Core Insights - Principal Financial Group Inc. acquired 45,205 shares of Stoke Therapeutics, valued at approximately $1,062,000, representing about 0.08% of the company [2] - Several institutional investors have increased their stakes in Stoke Therapeutics, indicating growing interest in the company [3] - Research firms have provided positive ratings and price targets for Stoke Therapeutics, suggesting a favorable outlook for the stock [4] Institutional Investment - Marshall Wace LLP increased its position by 7.9%, owning 2,300,554 shares valued at $26,111,000 after acquiring an additional 168,771 shares [3] - Goldman Sachs Group Inc. raised its stake by 21.4%, now holding 1,662,039 shares worth $11,053,000 after purchasing 293,072 shares [3] - Assenagon Asset Management S.A. boosted its position by 67.3%, owning 900,272 shares valued at $21,156,000 after acquiring 362,299 shares [3] Analyst Ratings - Guggenheim initiated coverage with a "buy" rating and a price target of $60.00 [4] - JPMorgan Chase & Co. raised its price target from $15.00 to $25.00, maintaining a "neutral" rating [4] - The consensus rating for Stoke Therapeutics is "Moderate Buy" with a target price of $39.18 [4] Stock Performance - Stoke Therapeutics shares opened at $30.98, with a 52-week low of $5.35 and a high of $38.69 [5] - The company has a market capitalization of $1.77 billion and a PE ratio of 46.24 [5] - The 50-day moving average price is $31.54, while the 200-day moving average price is $27.33 [5] Insider Activity - Director Edward M. Md Kaye sold 13,430 shares at an average price of $32.27, resulting in a 21.47% decrease in his position [6] - General Counsel Jonathan Allan sold 3,978 shares at an average price of $32.28, leading to a 25.16% decrease in his ownership [6] - Over the last 90 days, insiders sold 58,302 shares valued at $1,826,430, with insiders owning 9.50% of the company's stock [6] Company Overview - Stoke Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetic medicines for rare neuromuscular and neurological disorders [8] - The company utilizes its proprietary TANGO™ platform to design antisense oligonucleotides that enhance protein expression [8] - The lead program, STK-001, targets the sodium channel protein SCN1A for the treatment of Dravet syndrome [9]